IL2 and autoimmune uveitis: Our previous clinical trials of low‐dose IL‐2 therapy in systemic lupus erythematosus and Sjogren's syndrome have demonstrated that it could enhance antigen‐independent expansions of Treg cells,36, 37, 38 thus providing a strategy to improve the poor clonal expansion of Treg cells in autoimmune uveitis.